ALX ONCOLOGY HOLDINGS INC Long-Term Debt, Maturity, Year One
ALX ONCOLOGY HOLDINGS INC (ALXO) had Long-Term Debt, Maturity, Year One of $4.95 million as of 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths · last filed 2026-05-08
- 2026-03-31: Long-Term Debt, Maturity, Year One $4.95M.
- 2025-12-31: Long-Term Debt, Maturity, Year One $5.22M.
- 2025-09-30: Long-Term Debt, Maturity, Year One $5.22M.
- 2025-06-30: Long-Term Debt, Maturity, Year One $5.22M.
| Period end | Long-Term Debt, Maturity, Year One |
|---|---|
| 2026-03-31 | $4.95M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $5.22M 10-K · filed 2026-03-09 |
| 2025-09-30 | $5.22M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $5.22M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $5.22M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $435.00K 10-K · filed 2025-03-06 |
| 2024-09-30 | $435.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $435.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $435.00K 10-Q · filed 2024-05-09 |
| 2020-09-30 | $3.74M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $3.74M 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |